In recent years, the number of articles submitted to N2 has grown substantially. Currently, we are able to accept only a minority of submitted articles, and therefore, we must make difficult decisions regarding which articles will most benefit our readers and improve patient care. The extraordinary work of our reviewers facilitates this task. The dedication to reviewing for *Neurology® Neuroimmunology & Neuroinflammation* cannot be adequately conveyed. Your thoughtful comments regarding experimental research investigations, novel methods and techniques, studies that are particularly educational, or new strategies for the diagnosis and treatment of neurologic diseases are very helpful and highly appreciated.

Please send an email to nnnjournal@neurology.org if you would like to do more reviews or if you have never reviewed for the journal but are interested in doing so. Please include a description of your credentials and expertise in the areas in which you are qualified to review.

The reviewers listed below with 1 asterisk have reviewed 5 or more articles. Two asterisks indicate that the reviewer has reviewed 10 or more articles. This list includes those reviewers who returned a review or reviews of initial submissions (re-reviews of the same article are not included) between January 1, 2021, and December 31, 2021.

Just in case you are not familiar with your name, please note that the list is sorted by the first author's family name, and that it includes only those reviewers who submitted at least one review in 2021.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2022 The Author. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Disclosure

J. Dalmau is the Editor of Neurology: Neuroimmunology & Neuroinflammation, holds patents for the use of Ma2, NMDAR, GABABR, GABAAR, DPPX, and IgLON5 as autoantibody tests and receives royalties from the use of these tests. Go to Neurology.org/NN for full disclosures.
Acknowledgment to Reviewers
Josep O. Dalmau

Neurol Neuroimmunol Neuroinflamm 2022;9;
DOI 10.1212/NXI.0000000000001176

This information is current as of April 27, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/9/4/e1176.full.html

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus